This inventor holds 1 USPTO granted patent. Top assignee: Osi Pharmaceuticals, Inc.. Active years: 1999.
Company Filing History:
Years Active: 1999
Title: David Charles Billington: Innovator in Biosynthesis Enhancement
Introduction
David Charles Billington is a notable inventor based in West Midlands, GB. He has made significant contributions to the field of biochemistry, particularly in the development of compounds that enhance the biosynthesis of erythropoietin. His innovative work has implications for medical research and therapeutic applications.
Latest Patents
David Charles Billington holds a patent for "Tetracyclic compounds for enhancing biosynthesis of erythropoietin." This invention provides a compound in substantially pure form with a specific structure that includes various functional groups. The patent outlines the conditions under which these compounds can effectively modulate cellular expression of the mammalian gene encoding erythropoietin, which is crucial for red blood cell production.
Career Highlights
Billington is associated with Osi Pharmaceuticals, Inc., where he has been involved in groundbreaking research. His work has contributed to advancements in the understanding of erythropoietin and its applications in treating conditions related to anemia and other blood disorders.
Collaborations
Throughout his career, David has collaborated with notable colleagues, including Jonathan G Williams and David R Houck. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.
Conclusion
David Charles Billington's contributions to the field of biochemistry through his patent on tetracyclic compounds highlight his role as an innovator in enhancing erythropoietin biosynthesis. His work continues to influence medical research and therapeutic strategies.